Trial Profile
Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2008
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Romark Laboratories
- 03 Nov 2008 Results were presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and the 50th Anniversary Meeting of the International Association for the Study of the Liver (IASL).
- 17 Oct 2008 New trial record.